Literature DB >> 26052730

High prevalence of primary drug resistance in children with intrathoracic tuberculosis in India.

Suneel Prajapati1, Kriti Upadhyay1, Aparna Mukherjee2, S K Kabra2, Rakesh Lodha2, Varinder Singh3, Harleen M S Grewal4, Sarman Singh1.   

Abstract

BACKGROUND: Drug susceptibility testing (DST) of Mycobacterium tuberculosis (Mtb) isolates is crucial for the effective treatment of tuberculosis. Data on DST patterns in Mtb isolates in childhood tuberculosis are scanty. AIMS: To determine drug resistance patterns in Mtb isolates from a paediatric TB cohort in North India.
METHODS: 403 children aged 6 months to14 year with probable intrathoracic tuberculosis were enrolled prospectively. All were treatment-naïve. 802 ambulatory-induced sputa (IS) and 787 gastric aspirate (GA) samples were cultured in BACTEC-MGIT960 system, and DST of the Mtb isolates was undertaken using the automated BACTEC-MGIT960 SIRE kit.
RESULTS: Of the 403 children, 147 (36.4%) were culture-confirmed: 132 (89.8%) isolates were Mtb and 15 (10.2%) non-tuberculous mycobacteria (NTM). Five Mtb isolates were contaminated and the remaining 127 were subjected to in-vitro drug susceptibility testing against streptomycin, isoniazid, rifampicin and ethambutol. Twenty-six (20.47%) isolates were resistant to one or more drugs, seven (5.5%) were resistant to rifampicin singly or in combination, and 11 (8.7%) were resistant to isoniazid singly or in combination. Mono-resistance to isoniazid, rifampicin, streptomycin and ethambutol was detected in four (3.1%), one (0.8%), four (3.1%) and two (1.6%), respectively. Five children (3.9%) had MDR-TB; 101 (79.9%) children had Mtb isolates which were sensitive to all four drugs.
CONCLUSIONS: The rifampicin and isoniazid resistance rates were much higher than those in the adult TB population in India.

Entities:  

Keywords:  Gastric lavage; India; Induced sputum; Multi-drug-resistant TB; Rifampicin; Tuberculosis

Mesh:

Substances:

Year:  2016        PMID: 26052730     DOI: 10.1179/2046905515Y.0000000041

Source DB:  PubMed          Journal:  Paediatr Int Child Health        ISSN: 2046-9047            Impact factor:   1.990


  7 in total

Review 1.  Management of Latent Tuberculosis Infection in Children from Developing Countries.

Authors:  Agam Jain; Rakesh Lodha
Journal:  Indian J Pediatr       Date:  2019-02-11       Impact factor: 1.967

2.  Xpert MTB/RIF assay can be used on archived gastric aspirate and induced sputum samples for sensitive diagnosis of paediatric tuberculosis.

Authors:  Sarman Singh; Amit Singh; Suneel Prajapati; Sushil K Kabra; Rakesh Lodha; Aparna Mukherjee; Varinder Singh; Anneke C Hesseling; Harleen M S Grewal
Journal:  BMC Microbiol       Date:  2015-09-29       Impact factor: 3.605

Review 3.  Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.

Authors:  Aparna Mukherjee; Rakesh Lodha; Sushil Kumar Kabra
Journal:  Expert Opin Pharmacother       Date:  2017-10-09       Impact factor: 3.889

Review 4.  Prevalence of drug-resistant pulmonary tuberculosis in India: systematic review and meta-analysis.

Authors:  Vishal Goyal; Vijay Kadam; Prashant Narang; Vikram Singh
Journal:  BMC Public Health       Date:  2017-10-17       Impact factor: 3.295

5.  Epidemiology and Clinical Characteristics of Pediatric Drug-Resistant Tuberculosis in Chongqing, China.

Authors:  Qian Guo; Yun Pan; Zhenhua Yang; Ruixi Liu; Linlin Xing; Zhe Peng; Chaomin Zhu
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

6.  Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis.

Authors:  Emily A Kendall; Mariam O Fofana; David W Dowdy
Journal:  Lancet Respir Med       Date:  2015-11-18       Impact factor: 30.700

7.  The epidemiological characteristics and profile of drug-resistant tuberculosis among children with tuberculosis in Sichuan, China, 2015-2018: A retrospective study.

Authors:  Yuanhong Xu; Qingfeng Li; Ma Zhu; Xueqi Wu; Dongmei Wang; Jia Luo; Yingjie Li; Jing Zhong; Peibin Zeng
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.